Logo image
Back
Chronic kidney disease enhances alternative pathway activity: a new paradigm
Journal article   Open access   Peer reviewed

Chronic kidney disease enhances alternative pathway activity: a new paradigm

Diana I. Jalal, Joshua M. Thurman and Richard J.H. Smith
The Journal of clinical investigation, Vol.135(9), e188353
05/01/2025
DOI: 10.1172/JCI188353
PMCID: PMC12043098
PMID: 40309771
url
https://doi.org/10.1172/JCI188353View
Published (Version of record) Open Access

Abstract

Reduced kidney function is associated with increased risk of cardiovascular disease in addition to kidney disease progression. Kidney disease is considered an inflammatory state, based on elevated levels of C-reactive protein and inflammatory cytokines. A key mediator of cardiovascular and kidney disease progression in the setting of reduced kidney function is systemic and vascular inflammation. However, the exact pathways that link chronic kidney disease (CKD) with inflammation remain incompletely understood. For decades it has been known that factor D, the main activator of the alternative complement pathway, is increased in the plasma of patients with reduced kidney function. Recent biomarker evidence suggests alternative pathway activation in this setting. CKD, therefore, seems to alter the balance of alternative pathway proteins, promoting inflammation and potentially exacerbating complement-mediated diseases and CKD-associated complications. In this manuscript, we review the impact of reduced kidney function on biomarkers of the alternative complement pathway and the implications of alternative pathway activation on cardiovascular disease and kidney disease progression. Importantly, we highlight the need for ongoing research efforts that may lead to opportunities to target the alternative pathway of complement withx the goal of improving kidney and cardiovascular outcomes in persons with reduced kidney function.
 Review Series

Details

Metrics

1 Record Views
3 Times Cited - Web of Science
Logo image